| Market Cap | 1.86B | P/E | - | EPS this Y | 63.20% | Ern Qtrly Grth | - |
| Income | -304.34M | Forward P/E | -16.61 | EPS next Y | 53.90% | 50D Avg Chg | -17.00% |
| Sales | 251.18M | PEG | -0.32 | EPS past 5Y | - | 200D Avg Chg | -21.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 11.60% | 52W High Chg | -42.00% |
| Recommedations | 2.90 | Quick Ratio | 2.87 | Shares Outstanding | 104.18M | 52W Low Chg | 34.00% |
| Insider Own | 8.58% | ROA | -22.77% | Shares Float | 84.02M | Beta | 0.99 |
| Inst Own | 80.22% | ROE | - | Shares Shorted/Prior | 7.63M/9.26M | Price | 22.09 |
| Gross Margin | 38.44% | Profit Margin | -114.46% | Avg. Volume | 1,336,822 | Target Price | 8.95 |
| Oper. Margin | -52.79% | Earnings Date | Nov 4 | Volume | 1,018,168 | Change | -4.12% |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
| Barclays | Equal-Weight | Sep 13, 24 |
| Needham | Hold | Aug 13, 24 |
| Guggenheim | Neutral | Aug 12, 24 |
| William Blair | Market Perform | Aug 12, 24 |
| Piper Sandler | Overweight | Aug 9, 24 |
| Stifel | Buy | Aug 9, 24 |
| Needham | Buy | Aug 9, 24 |
| HC Wainwright & Co. | Buy | May 13, 24 |
| Goldman Sachs | Neutral | May 13, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Moxie Dwight | SVP, GC & Secretary SVP, GC & Secretary | Sep 05 | Sell | 17.44 | 34,853 | 607,836 | 44,066 | 09/07/23 |
| Foley Mark J | CEO CEO | Aug 03 | Sell | 22.5713 | 26,279 | 593,151 | 840,375 | 08/04/23 |
| Schilke Tobin | CFO CFO | Jun 30 | Sell | 25.04 | 1,701 | 42,593 | 79,896 | 07/05/23 |
| Foley Mark J | CEO CEO | Jun 30 | Sell | 24.94 | 26,279 | 655,398 | 866,654 | 07/05/23 |
| Sjuts Dustin S | President President | Jun 09 | Sell | 30.8192 | 5,000 | 154,096 | 147,347 | 06/13/23 |
| Foley Mark J | CEO CEO | Jun 09 | Sell | 30.7212 | 31,279 | 960,928 | 891,933 | 06/13/23 |
| Moxie Dwight | SVP, GC & Secretary SVP, GC & Secretary | Feb 02 | Sell | 34.55 | 21,401 | 739,405 | 69,165 | 05/16/23 |
| Schilke Tobin | CFO CFO | Feb 02 | Sell | 34.55 | 21,401 | 739,405 | 84,029 | 05/16/23 |
| Foley Mark J | CEO CEO | Feb 02 | Sell | 34.55 | 70,447 | 2,433,944 | 923,212 | 05/16/23 |
| Sjuts Dustin S | President President | Feb 02 | Sell | 34.55 | 21,015 | 726,068 | 152,347 | 05/16/23 |
| Moxie Dwight | SVP, GC & Secretary SVP, GC & Secretary | Sep 22 | Sell | 31.59 | 18,496 | 584,289 | 55,547 | 03/09/23 |
| Schilke Tobin | CFO CFO | Sep 22 | Sell | 31.59 | 18,517 | 584,952 | 73,222 | 03/09/23 |
| Sjuts Dustin S | President President | Sep 22 | Sell | 31.59 | 21,508 | 679,438 | 123,934 | 03/09/23 |
| Foley Mark J | CEO CEO | Sep 22 | Sell | 31.59 | 70,390 | 2,223,620 | 823,351 | 03/09/23 |
| Schilke Tobin | CFO CFO | Mar 01 | Sell | 33.50 | 3,201 | 107,234 | 49,390 | 03/02/23 |
| Schilke Tobin | CFO CFO | Jan 31 | Sell | 34.60 | 3,201 | 110,755 | 54,676 | 02/02/23 |
| Schilke Tobin | CFO CFO | Jan 20 | Sell | 31 | 1,000 | 31,000 | 57,877 | 01/23/23 |
| Schilke Tobin | CFO CFO | Jan 09 | Sell | 27.67 | 3,701 | 102,407 | 58,877 | 01/10/23 |